Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reddy’s Gets Six-Month Head Start On Carboprost In US

Executive Summary

Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.

You may also be interested in...



Amneal’s Amicar Rival Gets CGT Exclusivity

After receiving a CGT designation by the FDA for its generic version of Amicar, Amneal gets 180 days of exclusivity.

Reddy’s Will Look For Acquisitions Under New CEO Israeli

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Manufacturing Round-Up: Dr Reddy’s Receives Form 483 With Five Observations

As firms including Laurus Labs, Natco and Strides get GMP compliance nods, the FDA has pulled up Dr Reddy’s for GMP compliance issues. Meanwhile, Numaferm has struck a licensing deal and Olon has started constructing a new plant.

Related Content

Topics

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel